On December 6, 2025, Cogent Biosciences, Inc. reported successful outcomes from its SUMMIT clinical trial of bezuclastinib for nonadvanced systemic mastocytosis, showing significant improvements in patient symptoms, with 34.3% achieving over 50% reduction in symptom scores. Additionally, on December 8, 2025, positive top-line results were announced from the APEX trial for advanced systemic mastocytosis, with an 80% overall response rate and a plan to submit a new drug application to the FDA in early 2026.